Adaptive clinical trials in oncology.

Area of Science:

• Oncology Drug Development
• Clinical Trial Design
• Personalized Medicine

Background:

• Traditional oncology drug development faces escalating costs and low success rates in Phase III trials.
• Existing trial structures are often inefficient for addressing multiple research questions simultaneously.
• There is a need for more informative and adaptable clinical trial methodologies.

Purpose of the Study:

• To explore the utility of adaptive trial designs in modern oncology.
• To demonstrate how adaptive designs can optimize drug development processes.
• To highlight the role of adaptive trials in advancing personalized medicine.

Main Methods:

• Utilizing accumulating trial data to dynamically modify trial parameters.
• Employing longitudinal models of biomarkers, including imaging-based tumor burden, for endpoint prediction.
• Adopting a Bayesian perspective to enhance trial efficiency and accuracy.

Main Results:

• Adaptive designs allow for simultaneous evaluation of patient populations, dosages, regimens, and combinations.
• Longitudinal biomarker data enables prediction of primary endpoints, even in patients not achieving them.
• The I-SPY2 trial exemplifies a novel adaptive approach for evaluating multiple drugs within a single screening process.

Conclusions:

• Adaptive trial designs offer a more informative and efficient paradigm for oncology drug development.
• These designs facilitate personalized medicine by optimizing drug delivery and patient selection.
• Adaptive trials represent a significant advancement, exemplified by platforms like I-SPY2.